Lumida
/GILD
⌘K
Gilead Sciences Inc

Gilead Sciences Inc

GILD
$143.72USD-0.75%-1.09 today

MARKET CAP

178.2B

P/E (TTM)

FWD P/E

15.5x

DAY RANGE

$144 – $146

52W RANGE

$108
$157

AI Summary

Stalk
Sell NowMedium

GILD is in Stage 3 distribution with a bearish medium-term bias. Price is forming successive lower highs and lower lows below the declining 9/20 EMAs, signaling continued seller control. Short-term momentum confirms execution readiness, so selling into the dynamic resistance around the 9/20 EMA cluster (~144.90–146.45) is appropriate. Key support lies near 138.10, while the long-term uptrend remains intact but is currently overshadowed by the bearish structure.

  • Q2 product sales rose 10% YoY to $7.6B, driven by HIV portfolio
  • HIV sales up 12% to $5.7B, boosted by FDA approval of Bixlenvo
  • Operating margin stood at –94% in Q2, driven by major acquisition expenses
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$27.3B$27.3B$27.1B$28.8B$29.4B
YoY %+10.6%-0.1%-0.6%+6.0%+2.4%
P / Sales3.4x4.0x3.9x4.0x5.2x
EV / Sales4.9x5.3x5.1x5.1x6.2x
Gross Profit, Adj.$20.7B$21.6B$20.6B$22.5B$23.2B
YoY %+2.9%+4.4%-4.7%+9.1%+3.1%
Margin %75.8%79.3%76.0%78.3%78.8%
EV / Gross Profit6.4x6.7x6.7x6.5x7.9x
EBITDA, Adj.$12.9B$13.1B$11.5B$13.3B$14.4B
YoY %+132.5%+1.3%-12.0%+15.4%+8.5%
Margin %47.3%47.9%42.4%46.2%48.9%
EV / EBITDA10.3x11.0x12.0x11.0x12.7x
EBIT$9.9B$7.3B$7.6B$1.7B$10.0B
YoY %+143.6%-26.1%+3.8%-78.1%+503.0%
Margin %36.3%26.9%28.0%5.8%34.0%
EV / EBIT13.4x19.7x18.1x87.7x18.2x
Net Income$6.2B$4.6B$5.7B$480.0M$8.5B
YoY %+4961.0%-26.2%+23.4%-91.5%+1672.9%
Net Margin22.8%16.8%20.9%1.7%28.9%
EPS (GAAP)$4.93$3.64$4.50$0.38$6.78
YoY %+4830.0%-26.2%+23.6%-91.6%+1684.2%